Cargando…

High incidence of silent venous thromboembolism before treatment in ovarian cancer

Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD) before treatment in most ovarian cancer patients a...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, T, Oki, A, Uno, K, Sakurai, M, Ochi, H, Okada, S, Minami, R, Matsumoto, K, Tanaka, Y O, Tsunoda, H, Homma, S, Yoshikawa, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360447/
https://www.ncbi.nlm.nih.gov/pubmed/17895896
http://dx.doi.org/10.1038/sj.bjc.6603989
_version_ 1782153051786706944
author Satoh, T
Oki, A
Uno, K
Sakurai, M
Ochi, H
Okada, S
Minami, R
Matsumoto, K
Tanaka, Y O
Tsunoda, H
Homma, S
Yoshikawa, H
author_facet Satoh, T
Oki, A
Uno, K
Sakurai, M
Ochi, H
Okada, S
Minami, R
Matsumoto, K
Tanaka, Y O
Tsunoda, H
Homma, S
Yoshikawa, H
author_sort Satoh, T
collection PubMed
description Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD) before treatment in most ovarian cancer patients are increased. This study therefore examined whether increased levels of DD are associated with presence of VTE before treatment of ovarian cancer. Between November 2004 and March 2007, DD levels prior to initial treatment were measured in 72 consecutive patients with presumed epithelial ovarian cancer (final diagnosis: epithelial ovarian cancer, n=60; and epithelial ovarian borderline malignancy, n=12). Venous ultrasound imaging (VUI) of the lower extremity was conducted for all patients except for two patients in whom DVT was detected by pelvic computed tomography (CT). When DVT was found, pulmonary scintigraphy was subsequently performed to ascertain presence of PTE. D-dimer levels were above the cut-off value (0.5 μg ml(−1)) in 65 of 72 patients (90.2%). Venous ultrasound imaging or CT revealed DVT in 18 of 72 patients (25.0%) and pulmonary scintigraphy found PTE in 8 patients (11.1%). All patients with VTE were asymptomatic when VTE was found. D-dimer levels were associated with incidence of VTE (0–1.4 μg ml(−1); 0 of 26 (0%), 1.5–7.4 μg ml(−1); 9 of 30 (30%) and ⩾7.5 μg ml(−1); 9 of 16 (56.3%), P for trend=0.0003). However, even if 1.5 μg ml(−1) was used as a cut-off value, this had low specificity and positive predictive value (47.2, 38.3%), though it had high sensitivity and negative predictive value (100, 100%). Therefore, ovarian cancer patients with DD level ⩾1.5 μg ml(−1) should be examined using VUI to detect silent DVT. Patients with VTE underwent preventive managements including anticoagulant therapy before initial treatment, chemotherapy or surgery, and after surgery. There was no clinical onset of postoperative VTE in all 72 patients. Measurement of DD levels and subsequent ultrasonography revealed that silent or subclinical VTE frequently occurs before surgery in ovarian cancer. The usefulness of preoperative assessment of VTE needs further confirmation in randomised controlled trials.
format Text
id pubmed-2360447
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23604472009-09-10 High incidence of silent venous thromboembolism before treatment in ovarian cancer Satoh, T Oki, A Uno, K Sakurai, M Ochi, H Okada, S Minami, R Matsumoto, K Tanaka, Y O Tsunoda, H Homma, S Yoshikawa, H Br J Cancer Clinical Study Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD) before treatment in most ovarian cancer patients are increased. This study therefore examined whether increased levels of DD are associated with presence of VTE before treatment of ovarian cancer. Between November 2004 and March 2007, DD levels prior to initial treatment were measured in 72 consecutive patients with presumed epithelial ovarian cancer (final diagnosis: epithelial ovarian cancer, n=60; and epithelial ovarian borderline malignancy, n=12). Venous ultrasound imaging (VUI) of the lower extremity was conducted for all patients except for two patients in whom DVT was detected by pelvic computed tomography (CT). When DVT was found, pulmonary scintigraphy was subsequently performed to ascertain presence of PTE. D-dimer levels were above the cut-off value (0.5 μg ml(−1)) in 65 of 72 patients (90.2%). Venous ultrasound imaging or CT revealed DVT in 18 of 72 patients (25.0%) and pulmonary scintigraphy found PTE in 8 patients (11.1%). All patients with VTE were asymptomatic when VTE was found. D-dimer levels were associated with incidence of VTE (0–1.4 μg ml(−1); 0 of 26 (0%), 1.5–7.4 μg ml(−1); 9 of 30 (30%) and ⩾7.5 μg ml(−1); 9 of 16 (56.3%), P for trend=0.0003). However, even if 1.5 μg ml(−1) was used as a cut-off value, this had low specificity and positive predictive value (47.2, 38.3%), though it had high sensitivity and negative predictive value (100, 100%). Therefore, ovarian cancer patients with DD level ⩾1.5 μg ml(−1) should be examined using VUI to detect silent DVT. Patients with VTE underwent preventive managements including anticoagulant therapy before initial treatment, chemotherapy or surgery, and after surgery. There was no clinical onset of postoperative VTE in all 72 patients. Measurement of DD levels and subsequent ultrasonography revealed that silent or subclinical VTE frequently occurs before surgery in ovarian cancer. The usefulness of preoperative assessment of VTE needs further confirmation in randomised controlled trials. Nature Publishing Group 2007-10-22 2007-09-25 /pmc/articles/PMC2360447/ /pubmed/17895896 http://dx.doi.org/10.1038/sj.bjc.6603989 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Satoh, T
Oki, A
Uno, K
Sakurai, M
Ochi, H
Okada, S
Minami, R
Matsumoto, K
Tanaka, Y O
Tsunoda, H
Homma, S
Yoshikawa, H
High incidence of silent venous thromboembolism before treatment in ovarian cancer
title High incidence of silent venous thromboembolism before treatment in ovarian cancer
title_full High incidence of silent venous thromboembolism before treatment in ovarian cancer
title_fullStr High incidence of silent venous thromboembolism before treatment in ovarian cancer
title_full_unstemmed High incidence of silent venous thromboembolism before treatment in ovarian cancer
title_short High incidence of silent venous thromboembolism before treatment in ovarian cancer
title_sort high incidence of silent venous thromboembolism before treatment in ovarian cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360447/
https://www.ncbi.nlm.nih.gov/pubmed/17895896
http://dx.doi.org/10.1038/sj.bjc.6603989
work_keys_str_mv AT satoht highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT okia highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT unok highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT sakuraim highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT ochih highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT okadas highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT minamir highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT matsumotok highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT tanakayo highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT tsunodah highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT hommas highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer
AT yoshikawah highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer